Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iain McNeish

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Cancers|June 10, 2022
Risk Factors for Ovarian Cancer: An Umbrella Review of the LiteratureEilbhe Whelan, Ilkka Kalliala, Anysia Semertzidou, et al.
Journal for Immunotherapy of Cancer|December 11, 2021
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trialVictor Moreno, Maria-Pilar Barretina-Ginesta, Jesús García-Donas, et al.
British Journal of Cancer|January 20, 2024
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancerShibani Nicum, Naomi McGregor, Rachel Austin, et al.
BMJ Open|January 14, 2025
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancerUma Anne Mukherjee, Helen Hockings, Nicholas Counsell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2011
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancerJonathan A Ledermann, Allan Hackshaw, Stan Kaye, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 20, 2012
Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgeryAntonio Saha, Mohini Varughese, Chris J Gallagher, et al.
Oncogene|May 4, 2021
Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53Moshit Lindzen, Soma Ghosh, Ashish Noronha, et al.
Cell Reports|January 16, 2020
Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell ResponsesJulianna Blagih, Fabio Zani, Probir Chakravarty, et al.
Frontiers in Immunology|January 7, 2025
Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironmentVictoria A Jennings, Reah Rumbold-Hall, Gemma Migneco, et al.
Frontiers in Immunology|May 7, 2025
Corrigendum: Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironmentVictoria A Jennings, Reah Rumbold-Hall, Gemma Migneco, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Cancers|June 10, 2022
Risk Factors for Ovarian Cancer: An Umbrella Review of the LiteratureEilbhe Whelan, Ilkka Kalliala, Anysia Semertzidou, et al.
Journal for Immunotherapy of Cancer|December 11, 2021
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trialVictor Moreno, Maria-Pilar Barretina-Ginesta, Jesús García-Donas, et al.
British Journal of Cancer|January 20, 2024
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancerShibani Nicum, Naomi McGregor, Rachel Austin, et al.
BMJ Open|January 14, 2025
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancerUma Anne Mukherjee, Helen Hockings, Nicholas Counsell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2011
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancerJonathan A Ledermann, Allan Hackshaw, Stan Kaye, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 20, 2012
Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgeryAntonio Saha, Mohini Varughese, Chris J Gallagher, et al.
Oncogene|May 4, 2021
Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53Moshit Lindzen, Soma Ghosh, Ashish Noronha, et al.
Cell Reports|January 16, 2020
Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell ResponsesJulianna Blagih, Fabio Zani, Probir Chakravarty, et al.
Frontiers in Immunology|January 7, 2025
Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironmentVictoria A Jennings, Reah Rumbold-Hall, Gemma Migneco, et al.
Frontiers in Immunology|May 7, 2025
Corrigendum: Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironmentVictoria A Jennings, Reah Rumbold-Hall, Gemma Migneco, et al.
Pageof 7